NeurologiX: Parkinson`s Disease Phase 2 Trials Ongoing novel gene transfer approach
 

Parkinson`s Disease Phase 2 Trials Ongoing; Huntington`s Disease Nearing the Clinic

http://www.reuters.com/article/press...009+BW20090914

FORT LEE, N.J.--(Business Wire)--Neurologix, Inc. (OTCBB: NRGX), a biotechnology company engaged in the development of innovative gene therapies for the brain and central nervous system, announced today that the company will showcase its novel gene transfer approach to Parkinson`s disease and other serious brain and central nervous system diseases at the BioPharm America partnering conference being held in San Francisco, CA on September 17 - 18. John Mordock, Neurologix President and Chief Executive Officer, will discuss the company`s technology, ongoing Phase 2 trial in advanced Parkinson`s disease and other development programs from 4:15 - 4:30 on Thursday September 17 in Salon 14 at the Marriott San Francisco.